Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -24.44% | 155.79% | 265.23% | 40.45% | -37.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.44% | 155.79% | 265.23% | 40.45% | -37.79% |
| Cost of Revenue | 31.90% | 180.69% | 279.92% | -22.54% | -26.11% |
| Gross Profit | -43.84% | 141.49% | 251.01% | 132.17% | -40.98% |
| SG&A Expenses | 21.34% | -32.18% | -53.83% | -65.45% | -36.22% |
| Depreciation & Amortization | 34.66% | 17.28% | 18.81% | -12.93% | -31.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.17% | -12.66% | -36.38% | -56.55% | -35.81% |
| Operating Income | -63.13% | 38.40% | 55.43% | 61.53% | 34.62% |
| Income Before Tax | -66.04% | 22.72% | 47.34% | 82.27% | 31.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.04% | 22.72% | 47.34% | 82.27% | 31.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.04% | 22.72% | 47.34% | 82.27% | 31.26% |
| EBIT | -63.13% | 38.40% | 55.43% | 61.53% | 34.62% |
| EBITDA | -60.17% | 43.11% | 60.82% | 64.09% | 32.31% |
| EPS Basic | -64.29% | 23.19% | 48.05% | 81.87% | 34.38% |
| Normalized Basic EPS | -65.38% | 23.26% | 47.92% | 55.73% | 35.00% |
| EPS Diluted | -64.29% | 23.19% | 48.05% | 81.87% | 34.38% |
| Normalized Diluted EPS | -65.38% | 23.26% | 47.92% | 55.73% | 35.00% |
| Average Basic Shares Outstanding | 0.51% | 0.17% | 0.29% | -2.59% | 5.28% |
| Average Diluted Shares Outstanding | 0.51% | 0.17% | 0.29% | -2.59% | 5.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |